C4XD is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world‑leading medicines, developed by partners for the benefit of patients. It’s commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners. The company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals.
In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m, which is now in a Phase I clinical study.
In 2021, C4XD signed an exclusive worldwide licensing agreement with Sanofi worth up to €414 million, for C4XD’s oral pre-clinical IL-17A inhibitor programme.
Director Interviews
C4X Discovery announce 'sizeable deal and one we're very proud of' with Sanofi worth up to €414mln
Director Interviews
C4X Discovery Holdings says strong progress across the portfolio as commercial discussions continue
